Weight Management
April 20, 2026
·
5 min read
read
Ozempic vs Mounjaro: Which Weight Loss Injection Is Right for You?
Two names dominate almost every conversation about weight loss injections right now: Ozempic and Mounjaro. You've probably heard them from a friend, seen them trend on social media, or come across them during a late-night search spiral. But beyond the buzz, there are real — and clinically meaningful — differences between these two medications that matter when you're deciding which path is right for your body.
Two names dominate almost every conversation about weight loss injections right now: Ozempic and Mounjaro. You've probably heard them from a friend, seen them trend on social media, or come across them during a late-night search spiral. But beyond the buzz, there are real — and clinically meaningful — differences between these two medications that matter when you're deciding which path is right for your body.
This guide breaks down the science, the side-effect profiles, and the practical considerations so you can walk into a consultation with the right questions.
Ozempic contains semaglutide, a GLP-1 receptor agonist. It was originally approved to manage type 2 diabetes, but doctors noticed a consistent secondary effect: patients lost significant weight. Today, semaglutide at a higher dose (2.4 mg, marketed as Wegovy in some markets) is specifically licensed for chronic weight management. When people say "Ozempic for weight loss," they're usually referring to the semaglutide class of medication.
Mounjaro contains tirzepatide, a dual GIP/GLP-1 receptor agonist. That "dual" distinction is clinically important. Where semaglutide activates one receptor pathway (GLP-1), tirzepatide activates two — GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). Like semaglutide, tirzepatide was first approved for type 2 diabetes, with weight loss as a well-documented secondary effect.
Both are weekly injectable medications. Both work in part by slowing gastric emptying and reducing appetite. The difference lies in how — and how much.
This is where the conversation gets concrete. Let's look at what the studies actually found.
STEP 1 (semaglutide 2.4 mg, NEJM 2021)
The landmark STEP 1 trial enrolled 1 961 adults with obesity (BMI ≥30, or ≥27 with at least one weight-related comorbidity) without diabetes. Over 68 weeks, participants on semaglutide 2.4 mg achieved a mean body weight reduction of 14.9%, compared with 2.4% in the placebo group. Critically, 86.4% of participants in the semaglutide group achieved at least 5% weight loss, and nearly a third achieved ≥15%.
Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002.
SURMOUNT-1 (tirzepatide, NEJM 2022)
SURMOUNT-1 enrolled 2 539 adults with obesity. Over 72 weeks, mean weight reductions were dose-dependent: 15.0% at 5 mg, 19.5% at 10 mg, and 20.9% at the 15 mg dose — compared with 3.1% for placebo. At the highest dose, 57% of participants achieved ≥20% body weight reduction.
Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216.
SURMOUNT-5 (head-to-head, NEJM 2025)
SURMOUNT-5 was the trial the field had been waiting for: a direct comparison of tirzepatide versus semaglutide 2.4 mg in adults with obesity. Over 72 weeks, tirzepatide achieved a mean weight reduction of approximately 20.2%, while semaglutide achieved 13.7%. Tirzepatide demonstrated statistically superior weight loss at every time point assessed.
Wadden TA et al. Tirzepatide vs Semaglutide for Obesity (SURMOUNT-5). N Engl J Med. 2025.
The bottom line from the data: Both medications produce clinically meaningful weight loss. Tirzepatide consistently outperforms semaglutide in head-to-head and comparative analyses. But "more" is not always "better for you" — and that distinction matters.
Semaglutide (Ozempic / Wegovy):
GLP-1 receptor agonists mimic a hormone your gut releases after eating. By activating GLP-1 receptors in the brain and pancreas, semaglutide reduces appetite, slows the rate at which food leaves the stomach, and helps regulate blood sugar. The result: you feel full faster and stay full longer.
Tirzepatide (Mounjaro):
Tirzepatide does everything semaglutide does — and adds activation of GIP receptors. GIP plays a role in fat storage, energy metabolism, and may enhance the appetite-suppressing effects of GLP-1 signalling. The dual mechanism is believed to be the primary driver of tirzepatide's stronger weight loss outcomes in clinical trials.
Both medications share a similar gastrointestinal side-effect profile because of their overlapping GLP-1 mechanism.
Common side effects (both medications): - Nausea (most common, especially during dose escalation) - Vomiting - Diarrhoea - Constipation - Reduced appetite (this is often the mechanism, not just a side effect)
When side effects are most likely:
The first few weeks of treatment and after each dose increase. Most people find that GI symptoms ease significantly after 4–8 weeks as the body adjusts.
Less common but notable: - Headache - Fatigue - Injection site reactions
Contraindications for both:
Personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Both medications carry a boxed warning regarding thyroid C-cell tumours (observed in rodent studies; causal relationship in humans not established). People with a history of pancreatitis should discuss risk with their doctor.
Key difference in tolerability:
Head-to-head data from SURMOUNT-5 showed broadly similar rates of GI side effects between tirzepatide and semaglutide at their respective maximum doses. However, individual tolerance varies. Some people who experience significant nausea on semaglutide tolerate tirzepatide better, and vice versa.
There is no universal answer, and anyone who tells you otherwise is oversimplifying. Here's a framework for thinking it through with your doctor:
Consider your weight loss goal:
If your target is >15–20% body weight reduction, the clinical evidence supports tirzepatide as the stronger option. If ≥10–15% reduction would be meaningful and sufficient, semaglutide is well-evidenced.
Consider your medical history:
Both medications are approved for type 2 diabetes. If you have T2D alongside obesity, your doctor will factor in glycaemic control needs, existing medications, and cardiovascular risk. Semaglutide has stronger long-term cardiovascular outcome data (SELECT trial, SUSTAIN-6); tirzepatide's cardiovascular outcomes data is still emerging.
Consider access and cost:
Both medications are available in Singapore through licensed medical clinics with a valid prescription. Your doctor will confirm current availability and appropriate dosing for your situation.
Consider your starting point:
Both medications work best as part of a broader programme that includes dietary changes and increased physical activity. They are tools, not complete solutions.
Q: Can I take Ozempic or Mounjaro without a prescription in Singapore?
A: No. Both semaglutide and tirzepatide require a valid prescription from a licensed doctor in Singapore. They must not be purchased without medical supervision.
Q: How long do you need to stay on these medications?
A: Clinical trials ran for 68–72 weeks, but real-world data and current guidance suggest that weight regain typically occurs after stopping. Long-term use under medical supervision is the current clinical position for most patients.
Q: Which medication causes less nausea?
A: Individual responses vary. SURMOUNT-5 data showed similar overall GI side-effect profiles. Dose titration (starting low, increasing slowly) significantly reduces nausea severity for both.
Q: Is tirzepatide approved for weight loss specifically in Singapore?
A: Approval status changes over time. Consult your doctor or check the Health Sciences Authority (HSA) website for current licensing status. A prescribing doctor will advise on the most appropriate option given current approvals.
Q: Can these medications be combined with other weight loss treatments?
A: This should be determined by your doctor on a case-by-case basis. Combining weight loss medications without medical supervision is not recommended.
At Noah, we believe that access to clinically evidenced treatments should come with proper medical oversight — not workarounds. Our doctors review your health history, help you understand which medication aligns with your goals and risk profile, and support you through the titration process.
If you're ready to have a real conversation about weight loss injections with a doctor who takes the evidence seriously, start your consultation at ofnoah.sg.
This article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare professional before starting any weight loss medication.
